CD8A and neoplasm: RETA dramatically blunted LUAD onset, progression, and burden with significant changes in systemic anti-tumor immune cytokine IL-6, antigen presenting macrophages, and activated CD8+ T cells, with significantly reduced immunosuppressive cells, which together support that RETA leads to a broad and durable promotion of anti-tumor immunity.